Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.77 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.72 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | MGLL | Q99685 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13311774 | 0.87 | SMN1; SMN2 (0.74) | SMN1; SMN2NOTUMSIGMAR1HTTALDH1A1 | |
| SCHEMBL4019697 | 0.87 | SMN1; SMN2 (0.79) | SMN1; SMN2NOTUMSIGMAR1HTTALDH1A1 | |
| SCHEMBL29353444 | 0.85 | SMN1; SMN2 (0.77) | SMN1; SMN2NOTUMSIGMAR1HTTALDH1A1 | |
| SCHEMBL2829456 | 0.85 | SMN1; SMN2 (0.77) | SMN1; SMN2NOTUMSIGMAR1HTTALDH1A1 | |
| SCHEMBL5356744 | 0.84 | SMN1; SMN2 (0.74) | SMN1; SMN2NOTUMSIGMAR1HTTALDH1A1 | |
| SCHEMBL771590 | 0.84 | SMN1; SMN2 (0.74) | SMN1; SMN2NOTUMSIGMAR1HTTALDH1A1 | |
| SCHEMBL3120560 | 0.84 | SMN1; SMN2 (0.74) | SMN1; SMN2NOTUMSIGMAR1HTTALDH1A1 | |
| SCHEMBL330273 | 0.84 | SMN1; SMN2 (0.74) | SMN1; SMN2NOTUMSIGMAR1HTTALDH1A1 | |
| Hydrochloric Acid SCHEMBL11845665 | 0.84 | SMN1; SMN2 (0.74) | SMN1; SMN2NOTUMSIGMAR1HTTALDH1A1 | |
| SCHEMBL4295603 | 0.84 | SMN1; SMN2 (0.74) | SMN1; SMN2NOTUMSIGMAR1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | NR3C2, NR3C1, MC2R | SMN1; SMN2 4585/4885NOTUM 2577/4885SIGMAR1 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.